Ribociclib is primarily indicated for postmenopausal women and men with HR+, HER2- advanced or metastatic breast cancer. It is typically prescribed in combination with an aromatase inhibitor such as letrozole or an estrogen receptor antagonist like fulvestrant. The combination therapy helps to maximize the inhibition of cancer cell growth and offers a more robust treatment option.
